Pembrolizumab and Cabozantinib in Patients With Recurrent Metastatic HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial
Nat. Med. 2023 Apr 03;[EPub Ahead of Print], NF Saba, CE Steuer, A Ekpenyong, A McCook-Veal, K Magliocca, M Patel, NC Schmitt, W Stokes, JE Bates, S Rudra, J Remick, M McDonald, M Abousaud, AC Tan, MZH Fadlullah, R Chaudhary, J Muzaffar, K Kirtane, Y Liu, GZ Chen, DM Shin, Y Teng, CH ChungFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.